Mediaboss Marketing

BUCHAREST, ROMANIA--(Marketwire -06/11/12)- Bitdefender, the award-winning provider of innovative antivirus solutions, has launched a public beta test of a novel parental control system aimed at increasing open communication between parents and kids.

Bitdefender Parental Control, open to public beta testing on June 11th, allows parents to protect their children from online dangers by simply checking up on their mobile phone or any other Internet-connected device. With GPS tracking, parents know where their children are so they can protect them from real-world threats.

The Facebook monitoring feature identifies kids' profiles, allowing parents to monitor their social accounts without necessarily being on their friends' list. Extensive reports outline their children's friends, comments, posts, photos, and their main interests.

"Parental Control Standalone is loaded with features that help parents manage the dangers their kids are exposed to in the online environment," said Mihaela Masdrag, Product Manager at Bitdefender. "Most importantly, Bitdefender's parental control software monitors instead of blocks online content, promoting honest communication between parents and kids."

To this end, children have to allow the social media app when they enter into their account, but parents are also alerted when children uninstall access. "Honest communication is key to keeping children safe online and Bitdefender Parental Control facilitates that conversation, while leveraging proven technology to monitor for dangers and inappropriate content," Masdrag said.

Bitdefender Parental Control Standalone also gives beta testers the opportunity to try the online, user-friendly interface, which can be accessed from any Internet-connected device.

Bitdefender Standalone Parental Control module is available for free beta testing at: http://www.bitdefender.com/media/html/parental-control/

About Bitdefender

Bitdefender is the creator of one of the world's fastest and most effective lines of internationally certified internet security software. Since 2001, the company has been an industry pioneer, introducing and developing award-winning protection. Today, Bitdefender technology secures the digital experience of around 400 million home and corporate users across the globe.

Recently, the company won a range of key independent recommendations in the US, UK and across Europe, including ConsumerSearch, Stiftung Warentest and Taenk. Bitdefender antivirus technology has also finished top in leading industry tests from both AV Test and AV-Comparatives. More information about Bitdefender's antivirus products is available from the company's security solutions press room. Additionally, Bitdefender publishes the HOTforSecurity blog, a sizzling blend of steamy computer security stories and stimulating visuals that spotlights the seedy underworld of internet fraud, scams, malicious software -- and gossip.

See the original post:
Bitdefender Beta Tests Parental Control Standalone That Aids Parent-Child Communication

SAN DIEGO, June 11, 2012 (GLOBE NEWSWIRE) -- What is it about self-control that makes it so difficult to rely on? Self-control is a skill we all possess (honest); yet we tend to give ourselves little credit for it. Self-control is so fleeting for most that when Martin Seligman and his colleagues at the University of Pennsylvania surveyed two million people and asked them to rank order their strengths in 24 different skills, self-control ended up in the very bottom slot.

When it comes to self-control, it is so easy to focus on our failures that our successes tend to pale in comparison. And why shouldn't they? Self-control is an effort that's intended to help achieve a goal. Failing to control yourself is just that--a failure. If you're trying to avoid digging into that bag of chips after dinner because you want to lose a few pounds and you succeed Monday and Tuesday nights only to succumb to temptation on Wednesday by eating four servings' worth of the empty calories, your failure outweighs your success. You've taken two steps forward and four steps back.

With this success/failure dichotomy in mind, I give you six strategies for self-control that come straight from new research conducted at Florida State University. Some are obvious, others counterintuitive, but all will help you eliminate those pesky failures and ensure your efforts to boost your willpower are successful enough to keep you headed in the right direction for achieving your goals.

Self-Control Secret #1 -- Meditate

Meditation actually trains your brain to become a self-control machine. Even simple techniques like mindfulness, which involves taking as little as five minutes a day to focus on nothing more than your breathing and your senses, improves your self-awareness and your brain's ability to resist destructive impulses. Buddhist monks appear calm and in control for a reason.

Self-Control Secret #2 -- Eat

File this one in the counterintuitive category, especially if you're having trouble controlling your eating. Your brain burns heavily into your stores of glucose when attempting to exert self-control. If your blood sugar is low, you are far more likely to succumb to destructive impulses. Sugary foods spike your sugar levels quickly and leave you drained and vulnerable shortly thereafter. Eating something that provides a slow burn for your body, such as whole grain rice or meat, will give you a longer window of self-control. So, if you're having trouble keeping yourself out of the company candy bin when you're hungry, make sure you eat something else if you want to have a fighting chance.

Self-Control Secret #3 -- Exercise

Getting your body moving for as little as 10 minutes releases GABA, a neurotransmitter that makes your brain feel soothed and keeps you in control of your impulses. If you're having trouble resisting the impulse to walk over to the office next door to let somebody have it, just keep on walking. You should have the impulse under control by the time you get back.

Self-Control Secret #4 -- Sleep

The rest is here:
The Six Secrets of Self-Control

ATLANTA & NEW YORK, June 11, 2012 (GLOBE NEWSWIRE) -- Remark Media, Inc. (NASDAQ: MARK), a global digital media company, announces today four new additions to its management team in the areas of product, editorial, marketing and sales. The primary focus of the new management team members will be the growth and development of Remark Media's new product DimeSpring.com, a personal finance site that brings together leading financial experts to participate in an empowering conversation with consumers. The site offers interactive content, social sharing, and tools that enable users to take action on what they've learned.

"These new team members will play a major role in the implementation of the company's strategy of developing new proprietary content websites, starting in the personal finance sector with a focus on DimeSpring.com," said Remark Media CEO Carrie Ferman. "In addition, they will accelerate the efforts of our mission to provide immersive digital experiences that inform, entertain and inspire audiences worldwide."

Rob Sheppe, named Vice President of Product will drive product innovation efforts, as well as the implementation of a community-driven platform strategy. Prior to joining Remark Media, Sheppe served as Director, Product at Discovery Digital Media where he led platform-wide initiatives across Discovery Communication's portfolio for leading digital brands such as HowStuffWorks.com.

Mike Benzie joins as Director of Editorial Operations, responsible for managing content development. Benzie comes to the company from Yahoo!, where he helped launch and direct local news efforts. Previously, Benzie was an editor at the Atlanta Journal-Constitution, where he led the multimedia and photo departments and the AJC.com digital producer team.

Valerie Brown named Senior Director of Marketing joins from Time Out North America and will lead company-wide multi-platform marketing and social media efforts, including the activation of strategic digital partnerships. Prior to Time Out North America, Brown held key consumer and digital marketing positions at The Bravo Network and AgencyNet Interactive.

Kimberly Leon will serve as National Sales Director. Leon will be responsible for advancing the company's digital business development efforts, including the implementation of content and sponsorship focused advertising partnerships. Prior to joining Remark Media, Leon held management sales roles at CFO Publishing and Dow Jones.

About Remark Media:

Remark Media, Inc. (Nasdaq: MARK) is a global digital media company focused on creating destinations that merge engaging content with rich social interaction. Remark Media is the exclusive digital publisher in China and Brazil for translated content from HowStuffWorks.com, a subsidiary of Discovery Communications, and in China for certain content from World Book. The Company's leading brands, BoWenWang (bowenwang.com.cn) and ComoTudoFunciona (hsw.com.br), provide readers in China and Brazil with thousands of articles about how the world around them works, serving as destinations for credible, easy-to-understand reference information. Remark Media is also a founding partner and developer of the U.S.-based product Sharecare, a highly searchable social Q&A healthcare platform organizing and answering the questions of health. The Company is headquartered in Atlanta with additional operations in New York, Beijing and Sao Paulo. Additional information is available on its corporate website at remarkmedia.com.

Forward-Looking Statements:

This press release contains "forward-looking statements", as defined in Section 27A of the Securities Act of 1993, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be in the future tense, and often include words such as "anticipate", "expect", "project", "believe", "plan", "estimate", "intend", "will" and "may". These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of Remark Media. Relevant risks and uncertainties include those referenced in Remark Media's filings with the SEC, and include but are not limited to: our losses and need to raise capital; successfully developing and launching new digital media properties; restrictions on intellectual property under agreements with Sharecare and third parties; challenges inherent in developing an online business; reliance on key personnel; general industry conditions and competition; and general economic conditions, such as advertising rate, interest rate and currency exchange rate fluctuations. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. Remark Media assumes no obligation to update any forward-looking statements as a result of new information or future events or developments, except as required by law.

See more here:
Remark Media Names New Product, Editorial, Marketing and Sales Management Team

PHILADELPHIA, June 11, 2012 /PRNewswire/ --Halozyme Therapeutics, Inc. (HALO) today announced results from a Phase 2 study of prandial insulin formulations, which include the Company's recombinant human hyaluronidase (rHuPH20) enzyme, in patients with Type 1 diabetes. The study met its primary endpoint of A1C non-inferiority (A1C is a measure of average blood sugar over three months). Further, data from the study indicated that rHuPH20 reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. These findings were presented in an oral presentation at the 72nd Scientific Sessions of the American Diabetes Association (ADA) on Monday, June 11 from 6:15 - 6:30 PM EDT.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"There is a real need for faster-acting mealtime insulins. By accelerating the absorption and action of prandial insulins, rHuPH20 may help reduce mealtime glucose fluctuations that make managing diabetes difficult," said Irl B. Hirsch, M.D., Professor of Medicine, Diabetes Treatment and Teaching Chair, University of Washington School of Medicine. "This faster-in, faster-out profile may also attenuate the risk of hypoglycemia. In this study, improved control of mealtime glucose significantly reduced hypoglycemic events in patients receiving treatments with the rHuPH20 enzyme. The data further indicated that Halozyme's ultrafast insulin formulations moderate glucose swings, thus more closely mimicking the effects of endogenous insulin and, if approved, could ultimately help patients with diabetes live healthier lives."

The study compared two rapid acting insulin analog products (lispro or aspart), formulated with rHuPH20 (lispro-PH20 and aspart-PH20, each an Analog-PH20), to an active comparator (lispro alone). The study met the primary endpoint, showing that the Analog-PH20 formulations were non-inferior for A1C, compared to lispro alone (0.4% margin) with no treatment difference (95% CI -.05, +.15). Patient groups in all treatment arms of this study achieved excellent blood glucose control, with endpoint A1C values <6.9%. Data from the study also showed that mean post-meal glycemic excursions (measured at 90 minutes) in the patient groups treated with Analog-PH20 were reduced by 82 percent (p=.0045), with more patients consistently achieving post-prandial glucose targets for at least two-thirds of their meals, as compared with the patient group treated with lispro alone. For those patient groups treated with Analog-PH20, overall hypoglycemic rates as defined by the ADA (glucose <70 mg/dL) were reduced by 5 percent (p=.035) and hypoglycemic events as defined by a more stringent definition (glucose <56 mg/dL) by 7 percent (p=.044), as compared with the patient group treated with lispro alone.

Additionally, over the 12 week study period total daily insulin dose with the Analog-PH20 treatment groups was comparable (54+27 U vs. 56+27 U, p=.057) as was weight change (-0.25 lbs. vs. +0.10 lbs., p=.27), compared with the patient group treated with lispro alone. Adverse events were also comparable between treatments, with no meaningful difference in adverse events, immunogenicity or injection site pain and Analog-PH20 was well tolerated. Treatment phase severe adverse events were limited to hypoglycemia, which occurred in two subjects treated with lispro alone.

Study Design

This 30 week, randomized, double-blind, two-way cross-over safety and efficacy study compared subcutaneously injected Analog-PH20 versus lispro alone in patients with Type 1 diabetes who were an average age of 43+14 years and had been treated with insulin for> 12 months. The study enrolled 117 patients with an average Body Mass Index (BMI) of 27.3+4.0, and A1C of 7.0+.5 percent. After a four to six week run-in period using prandial glulisine plus twice-daily glargine, patients were randomized to lispro-PH20 or aspart-PH20 versus lispro alone for two, 12-week intensive management periods. Prandial therapy was administered immediately before meals. The primary endpoint of the study was A1C non-inferiority. Secondary outcomes included rates of hypoglycemia, insulin dose, change in body weight, along with blood glucose measures.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at http://www.halozyme.com.

Safe Harbor Statement

View post:
Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 ...

PARIS, France, June 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SANand NYSE: SNY) announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin. These data from the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients) study were presented at the American Diabetes Association 72nd Scientific Sessions. Results of the study were also published today online in The Lancet.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO)

"The findings of this study comparing insulin glargine with sitagliptin provide evidence to support the recent ADA-EASD proposal to consider early basal insulin therapy as add-on to metformin to help achieve glycemic control in people with type 2 diabetes," said principal investigator Pablo Aschner, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Colombia.

In insulin-naive people with type 2 diabetes, who were inadequately controlled by metformin once-daily, insulin glargine produced superior HbA1c reduction (-1.7%) versus once daily sitagliptin (-1.1%; p<0.001). Notably 50% more patients on insulin glargine achieved HbA1c <7% (68 vs. 42%) and <6.5% (40 vs. 17%) compared to sitagliptin (p<0.0001 for both), indicating improved glycemic control for a greater number of insulin glargine patients. Additionally, a statistically significant improvement in fasting plasma glucose (FPG), a key contributor to glycemic control, was observed for patients on insulin glargine compared to sitagliptin. The mean difference in self-monitored FPG was -41.4 mg/dL (95% CI: -46.8 to -36.0 mg/dL) lower with insulin glargine than with sitagliptin (p<0.0001).

Treatment-emergent adverse events were less frequent in patients on insulin glargine (108 patients [46%]) versus sitagliptin (143 patients [54%]). Hypoglycemia rates were higher with insulin glargine (4.21 events per patient year versus 0.50 for sitagliptin; p<0.0001). The number of patients with overall symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia, with plasma glucose (PG) < 56 mg/dL, was 56 with insulin glargine compared to 12 with sitagliptin, and 20 vs. 2, respectively. Severe symptomatic hypoglycemia was reported in 3 patients receiving insulin glargine compared to 1 receiving sitagliptin. Severe nocturnal symptomatic hypoglycemia was reported in 1 patient in each group. Mean body weight slightly increased with glargine (+0.4 kg) and decreased with sitagliptin (-1.1 kg).

"The EASIE study adds valuable data to further strengthen the efficacy profile of Lantus when initiated early in the treatment pathway after metformin," said Pierre Chancel, Senior Vice President, Global Diabetes, Sanofi. "EASIE is a demonstration of the continued commitment of Sanofi to helping people with type 2 diabetes reach their glycemic targets."

The study findings are highlighted at the American Diabetes Association Scientific Sessions in the following abstract: Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naive Patients (EASIE) With Type 2 Diabetes Mellitus (T2DM) Uncontrolled in Metformin (Aschner et al.) [CT-SY22].

About EASIEEASIE was a multicenter, international, randomized, open-label, six-month study that compared once-daily insulin glargine with sitagliptin (100 mg) once daily, as add-on therapy to metformin, in insulin-naive people with early type 2 diabetes (median disease duration after diagnosis: 4.5 years). The primary endpoint was to demonstrate superiority of insulin glargine (n = 227 at study end) over sitagliptin (n = 253 at study end) in change in HbA1c from baseline to study end. Baseline characteristics were similar for both groups.

About Lantus (insulin glargine [rDNA origin] injection)Prescription Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and children (6 years and older) with type 1 diabetes for the control of high blood sugar. It should be taken once a day at the same time each day to lower blood glucose.

Do not use Lantus to treat diabetic ketoacidosis.

See more here:
Lantus® Initiation after Metformin Achieved Superior Glycemic Control versus Sitagliptin in Type 2 Diabetes